Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Your search for process/pmg6 returned no results
Showing 286 to 300 of 2854 results for process

  1. Luspatercept for treating anaemia caused by myelodysplastic syndromes (terminated appraisal) (TA844)

    NICE is unable to make a recommendation on luspatercept (Reblozyl) for treating anaemia caused by myelodysplastic syndromes because BMS did not provide an evidence submission.

    Technology appraisal guidance
    Published
    24 November 2022

    Sections for TA844

  2. Mepolizumab for treating severe hypereosinophilic syndrome (terminated appraisal) (TA846)

    NICE is unable to make a recommendation on mepolizumab (Nucala) for treating severe hypereosinophilic syndrome in adults because GSK did not provide an evidence submission.

    Technology appraisal guidance
    Published
    29 November 2022

    Sections for TA846

  3. Eculizumab for treating relapsing neuromyelitis optica (terminated appraisal) (TA647)

    NICE is unable to make a recommendation on eculizumab (Soliris) for treating relapsing neuromyelitis optica because Alexion Pharma UK did not provide an evidence submission.

    Technology appraisal guidance
    Published
    2 September 2020

    Sections for TA647

  4. Daratumumab with bortezomib, melphalan and prednisone for untreated multiple myeloma (terminated appraisal) (TA771)

    NICE is unable to make a recommendation on daratumumab (Darzalex) with bortezomib, melphalan and prednisone for untreated multiple myeloma because Janssen did not provide an evidence submission.

    Technology appraisal guidance
    Published
    9 February 2022

    Sections for TA771

  5. NBTXR-3 for treating advanced soft tissue sarcoma (terminated appraisal) (TA745)

    NICE is unable to make a recommendation on NBTXR-3 for treating advanced soft tissue sarcoma. This is because Nanobiotix did not provide an evidence submission.

    Technology appraisal guidance
    Published
    10 November 2021

    Sections for TA745

  6. Eculizumab for treating refractory myasthenia gravis (terminated appraisal) (TA636)

    NICE is unable to make a recommendation on eculizumab (Soliris) for treating refractory myasthenia gravis. This is because Alexion Pharma UK did not provide an evidence submission.

    Technology appraisal guidance
    Published
    30 June 2020

    Sections for TA636

  7. Ibrutinib with rituximab for treating Waldenstrom's macroglobulinaemia (terminated appraisal) (TA608)

    NICE is unable to make a recommendation on ibrutinib (Imbruvica) with rituximab for treating Waldenstrom’s macroglobulinaemia in adults. This is because Janssen did not provide an evidence submission.

    Technology appraisal guidance
    Published
    30 October 2019

    Sections for TA608

  8. Ibrutinib with rituximab for untreated chronic lymphocytic leukaemia (terminated appraisal) (TA703)

    NICE is unable to make a recommendation on ibrutinib (Imbruvica) with rituximab for untreated chronic lymphocytic leukaemia because Janssen did not provide an evidence submission.

    Technology appraisal guidance
    Published
    26 May 2021

    Sections for TA703

  9. Iptacopan for treating complement 3 glomerulopathy (terminated appraisal) (TA1102)

    NICE is unable to make a recommendation on iptacopan (Fabhalta) for treating complement 3 glomerulopathy in adults. This is because the company has withdrawn from the appraisal.

    Technology appraisal guidance
    Published
    29 October 2025

    Sections for TA1102

  10. Nivolumab with chemotherapy for untreated unresectable or metastatic urothelial cancer (terminated appraisal) (TA1141)

    NICE is unable to make a recommendation on nivolumab (Opdivo) for untreated unresectable or metastatic urothelial cancer. This is because the company did not provide an evidence submission.

    Technology appraisal guidance
    Published
    17 March 2026

    Sections for TA1141

  11. Mepolizumab for treating severe chronic rhinosinusitis with nasal polyps (terminated appraisal) (TA847)

    NICE is unable to make a recommendation on mepolizumab (Nucala) for treating severe chronic rhinosinusitis with nasal polyps in adults because GSK did not provide an evidence submission.

    Technology appraisal guidance
    Published
    29 November 2022

    Sections for TA847

  12. Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm (terminated appraisal) (TA782)

    NICE is unable to make a recommendation on tagraxofusp (Elzonris) for treating blastic plasmacytoid dendritic cell neoplasm. This is because Stemline Therapeutics did not provide an evidence submission.

    Technology appraisal guidance
    Published
    30 March 2022

    Sections for TA782

  13. Nivolumab with cabozantinib for untreated advanced renal cell carcinoma (terminated appraisal) (TA785)

    NICE is unable to make a recommendation on nivolumab (Opdivo) with cabozantinib for untreated advanced renal cell carcinoma. This is because Bristol Myers Squibb withdrew the evidence submission.

    Technology appraisal guidance
    Published
    20 April 2022

    Sections for TA785

  14. TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices (terminated appraisal) (TA790)

    NICE is unable to make a recommendation on TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices because Medtronic withdrew its evidence submission.

    Technology appraisal guidance
    Published
    25 May 2022

    Sections for TA790

  15. Durvalumab in combination for untreated extensive-stage small-cell lung cancer (terminated appraisal) (TA662)

    NICE is unable to make a recommendation on durvalumab (Imfinzi) in combination for untreated extensive-stage small-cell lung cancer in adults because AstraZeneca withdrew its evidence submission.

    Technology appraisal guidance
    Published
    25 November 2020

    Sections for TA662